Blood-brain barrier (BBB) pharmacoproteomics: A new research field opened up by quantitative targeted absolute proteomics (QTAP)

AAPS Advances in the Pharmaceutical Sciences Series

Volumn 10, Issue , 2014, Pages 63-100

  Uchida, Yasuo ^a   Tachikawa, Masanori ^a   Ohtsuki, Sumio ^b   Terasaki, Tetsuya ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IODOTHYRONINE; THYROXINE; ABC TRANSPORTER A1; ABC TRANSPORTER A2; ABC TRANSPORTER A8; ALBUMIN; BREAST CANCER RESISTANCE PROTEIN; CD147 ANTIGEN; CYTOCHROME P450 2B6; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; EXCITATORY AMINO ACID TRANSPORTER 3; GLUCOSE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 3; ORGANIC ANION TRANSPORTER B; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A2; TAURINE TRANSPORTER; TRYPSIN;

AMINO ACID SEQUENCE; ARTICLE; BINDING ASSAY; BLOOD BRAIN BARRIER; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG SOLUBILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; LIQUID CHROMATOGRAPHY; MATHEMATICAL MODEL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION ASSAY; PROTEIN POLYMORPHISM; PROTEOMICS; QUANTITATIVE ANALYSIS; QUANTITATIVE TARGETED ABSOLUTE PROTEOMICS; REACTION ANALYSIS; RNA ANALYSIS; SCREENING; SENSITIVITY AND SPECIFICITY; SINGLE CELL ANALYSIS; SPECIES DIFFERENCE; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS; BREAST CANCER; GENE EXPRESSION; HUMAN; IMMUNOBLOTTING; MULTIPLE REACTION MONITORING; MULTIPLEXED SELECTED REACTION MONITORING; NONHUMAN; PANCREAS ADENOCARCINOMA; PHARMACOPROTEOMICS; PROTEIN EXPRESSION; QUANTITATIVE TARGETED ABSOLUTE QUANTITATIVE TARGETED ABSOLUTE; STOMACH CANCER; TIME;

EID: 84905011656     PISSN: 22107371     EISSN: 2210738X     Source Type: Book Series    
DOI: 10.1007/978-1-4614-9105-7_3     Document Type: Article

References (80)

1. Adachi Y, Suzuki H, Sugiyama Y (2001) Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res 18:1660-1668
2. Aebersold R, Mann M (2003) Mass spectrometry-based proteomics. Nature 422:198-207
3. Ang CS, Phung J, Nice EC (2011) The discovery and validation of colorectal cancer biomarkers. Biomed Chromatogr 25:82-99
4. Arriza JL, Fairman WA, Wadiche JI, Murdoch GH, Kavanaugh MP, Amara SG (1994) Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J Neurosci 14:5559-5569
5. Bauer M, Zeitlinger M, Karch R, Matzneller P, Stanek J, Jager W, Bohmdorfer M, Wadsak W, Mitterhauser M, Bankstahl JP, Loscher W, Koepp M, Kuntner C, Muller M, Langer O (2012) Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. Clin Pharmacol Ther 91:227-233
6. Ceballos A, Belinchon MM, Sanchez-Mendoza E, Grijota-Martinez C, Dumitrescu AM, Refetoff S, Morte B, Bernal J (2009) Importance of monocarboxylate transporter 8 for the blood-brain barrier-dependent availability of 3,5,3′-triiodo-L-thyronine. Endocrinology 150:2491-2496
7. Chen C, Hanson E, Watson JW, Lee JS (2003) P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 31:312-318
8. Chen P, Li X, Sun Y, Liu Z, Cao R, He Q, Wang M, Xiong J, Xie J, Wang X, Liang S (2006) Proteomic analysis of rat hippocampal plasma membrane: characterization of potential neuronal-specific plasma membrane proteins. J Neurochem 98:1126-1140
9. Ciccimaro E, Hanks SK, Yu KH, Blair IA (2009) Absolute quantification of phosphorylation on the kinase activation loop of cellular focal adhesion kinase by stable isotope dilution liquid chromatography/ mass spectrometry. Anal Chem 81:3304-3313
10. de Vries NA (2009) Preclinical models to study the impact of the blood-brain barrier in brain tumor chemotherapy. Doctor’s thesis, Division of Clinical Chemistry, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands and Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, The Netherlands
11. Domanski D, Murphy LC, Borchers CH (2010) Assay development for the determination of phosphorylation stoichiometry using multiple reaction monitoring methods with and without phosphatase treatment: application to breast cancer signaling pathways. Anal Chem 82:5610-5620
12. Domon B, Aebersold R (2006) Mass spectrometry and protein analysis. Science 312:212-217
13. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, Cox LM, Gibbs JP, Gibbs MA, Hatch H, Hop CE, Kasman IN, Laperle J, Liu J, Liu X, Logman M, Maclin D, Nedza FM, Nelson F, Olson E, Rahematpura S, Raunig D, Rogers S, Schmidt K, Spracklin DK, Szewc M, Troutman M, Tseng E, Tu M, Van Deusen JW, Venkatakrishnan K, Walens G, Wang EQ, Wong D, Yasgar AS, Zhang C (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33: 165-174
14. Dyer J, Barker PJ, Shirazi-Beechey SP (1997) Nutrient regulation of the intestinal Na+/glucose co-transporter (SGLT1) gene expression. Biochem Biophys Res Commun 230:624-629
15. Frank R, Hargreaves R (2003) Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2:566-580
16. Friden M, Gupta A, Antonsson M, Bredberg U, Hammarlund-Udenaes M (2007) In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos 35:1711-1719
17. Friden M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, Hammarlund-Udenaes M, Antonsson M (2009) Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem 52:6233-6243
18. Friden M, Bergstrom F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, Bredberg U (2011) Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos 39:353-362
19. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC (2002) Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59:1381-1389
20. Hendrikse NH, Schinkel AH, De Vries EG, Fluks E, Van Der Graaf WT, Willemsen AT, Vaalburg W, Franssen EJ (1998) Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 124: 1413-1418
21. Heuer H (2007) The importance of thyroid hormone transporters for brain development and function. Best Pract Res Clin Endocrinol Metab 21:265-276
22. Hoffmeyer S, Burk O, Von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97:3473-3478
23. Hosoya K, Sugawara M, Asaba H, Terasaki T (1999) Blood-brain barrier produces significant efflux of L-aspartic acid but not D-aspartic acid: in vivo evidence using the brain efflux index method. J Neurochem 73:1206-1211
24. Ito K, Uchida Y, Ohtsuki S, Aizawa S, Kawakami H, Katsukura Y, Kamiie J, Terasaki T (2011) Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J Pharm Sci 100:3939-3950
25. Izumi Y, Tokuda K, O’dell KA, Zorumski CF, Narahashi T (2007) Neuroexcitatory actions of Tamiflu and its carboxylate metabolite. Neurosci Lett 426:54-58
26. Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, Sekine Y, Uchida Y, Ito S, Terasaki T (2008) Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res 25:1469-1483
27. Kanai Y, Trotti D, Nussberger S, Hediger MA (1997) The highaffinity glutamate transporter family. In: Reith MEA (ed) Neurotransmitter transporters: structure, function, and regulation. Humana Press, Totowa, NJ, pp 171-213
28. Kawakami H, Ohtsuki S, Kamiie J, Suzuki T, Abe T, Terasaki T (2011) Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with In silico target peptide selection. J Pharm Sci 100:341-352
29. Kemper EM, Cleypool C, Boogerd W, Beijnen JH, Van Tellingen O (2004) The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemother Pharmacol 53:173-178
30. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294
31. Kito K, Ota K, Fujita T, Ito T (2007) A synthetic protein approach toward accurate mass spectrometric quantification of component stoichiometry of multiprotein complexes. J Proteome Res 6:792-800
32. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715
33. Kusuhara H, Sugiyama Y (2009) In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet 24:37-52
34. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H (1999) Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem 274:13675-13680
35. Langenfeld E, Zanger UM, Jung K, Meyer HE, Marcus K (2009) Mass spectrometry-based absolute quantification of microsomal cytochrome P450 2D6 in human liver. Proteomics 9: 2313-2323
36. Li N, Nemirovskiy OV, Zhang Y, Yuan H, Mo J, Ji C, Zhang B, Brayman TG, Lepsy C, Heath TG, Lai Y (2008) Absolute quantification of multidrug resistance-associated protein 2 (MRP2/ABCC2) using liquid chromatography tandem mass spectrometry. Anal Biochem 380:211-222
37. Loscher W, Potschka H (2005) Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6:591-602
38. Miller DS, Bauer B, Hartz AM (2008) Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev 60: 196-209
39. Nagano K, Taoka M, Yamauchi Y, Itagaki C, Shinkawa T, Nunomura K, Okamura N, Takahashi N, Izumi T, Isobe T (2005) Large-scale identification of proteins expressed in mouse embryonic stem cells. Proteomics 5:1346-1361
40. Niessen J, Jedlitschky G, Grube M, Bien S, Schwertz H, Ohtsuki S, Kawakami H, Kamiie J, Oswald S, Starke K, Strobel U, Siegmund W, Rosskopf D, Greinacher A, Terasaki T, Kroemer HK (2009) Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos 37:1129-1137
41. Niessen J, Jedlitschky G, Grube M, Kawakami H, Kamiie J, Ohtsuki S, Schwertz H, Bien S, Starke K, Ritter C, Strobel U, Greinacher A, Terasaki T, Kroemer HK (2010) Expression of ABC-type transport proteins in human platelets. Pharmacogenet Genomics 20:396-400
42. Obuchi W, Ohtsuki S, Uchida Y, Ohmine K, Yamori T, Terasaki T (2013) Identification of transporters associated with etoposide sensitivity of stomach cancer cell lines and methotrexate sensitivity of breast cancer cell lines by quantitative targeted absolute proteomics. Mol Pharmacol 83:490-500. doi:10.1124/mol.112.081083
43. Ohmine K, Kawaguchi K, Ohtsuki S, Motoi F, Egawa S, Unno M, Terasaki T (2012) Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells. Pharm Res 29:2006-2016
44. Ohtsuki S, Terasaki T (2007) Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res 24:1745-1758
45. Ohtsuki S, Uchida Y, Kubo Y, Terasaki T (2011) Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. J Pharm Sci 100:3547-3559
46. Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, Saito A, Ishiguro N, Kishimoto W, Ludwig-Schwellinger E, Ebner T, Terasaki T (2012) Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos 40:83-92
47. Ohtsuki S, Ikeda C, Uchida Y, Sakamoto Y, Miller F, Glacial F, Decleves X, Scherrmann JM, Couraud PO, Kubo Y, Tachikawa M, Terasaki T (2013) Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model. Mol Pharm 10:289-296. doi:10.1021/mp3004308
48. O’kane RL, Martinez-Lopez I, Dejoseph MR, Vina JR, Hawkins RA (1999) Na(+)-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier. A mechanism for glutamate removal. J Biol Chem 274:31891-31895
49. Ose A, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, Fujita T, Yamamoto A, Sugiyama Y (2008) P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Drug Metab Dispos 36:427-434
50. Ose A, Ito M, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, Hosokawa M, Schuetz JD, Sugiyama Y (2009) Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxyl ate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos 37:315-321
51. Pardridge WM (2002) Why is the global CNS pharmaceutical market so under-penetrated? Drug Discov Today 7:5-7
52. Patterson SD, Aebersold RH (2003) Proteomics: the first decade and beyond. Nat Genet 33 Suppl:311-323
53. Pshezhetsky AV, Fedjaev M, Ashmarina L, Mazur A, Budman L, Sinnett D, Labuda D, Beaulieu JF, Menard D, Nifant’ev I, Levy E (2007) Subcellular proteomics of cell differentiation: quantitative analysis of the plasma membrane proteome of Caco-2 cells. Proteomics 7:2201-2215
54. Roberts LM, Woodford K, Zhou M, Black DS, Haggerty JE, Tate EH, Grindstaff KK, Mengesha W, Raman C, Zerangue N (2008) Expression of the thyroid hormone transporters monocarboxylate transporter-8 (SLC16A2) and organic ion transporter-14 (SLCO1C1) at the blood-brain barrier. Endocrinology 149:6251-6261
55. Sakata S, Fujiwara M, Ohtsuka K, Kamma H, Nagane M, Sakamoto A, Fujioka Y (2011) ATP-binding cassette transporters in primary central nervous system lymphoma: decreased expression of MDR1 P-glycoprotein and breast cancer resistance protein in tumor capillary endothelial cells. Oncol Rep 25:333-339
56. Schwamborn K, Caprioli RM (2010) MALDI imaging mass spectrometry-painting molecular pictures. Mol Oncol 4:529-538
57. Shawahna R, Uchida Y, Decleves X, Ohtsuki S, Yousif S, Dauchy S, Jacob A, Chassoux F, Daumas-Duport C, Couraud PO, Terasaki T, Scherrmann JM (2011) Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol Pharm 8:1332-1341
58. Shirasaka Y, Sakane T, Yamashita S (2008) Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J Pharm Sci 97:553-565
59. Sugiura Y, Setou M (2010) Imaging mass spectrometry for visualization of drug and endogenous metabolite distribution: toward in situ pharmacometabolomes. J Neuroimmune Pharmacol 5:31-43
60. Summerfield SG, Lucas AJ, Porter RA, Jeffrey P, Gunn RN, Read KR, Stevens AJ, Metcalf AC, Osuna MC, Kilford PJ, Passchier J, Ruffo AD (2008) Toward an improved prediction of human in vivo brain penetration. Xenobiotica 38:1518-1535
61. Syvanen S, Lindhe O, Palner M, Kornum BR, Rahman O, Langstrom B, Knudsen GM, Hammarlund-Udenaes M (2009) Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos 37:635-643
62. Tachibana T, Kitamura S, Kato M, Mitsui T, Shirasaka Y, Yamashita S, Sugiyama Y (2010) Model analysis of the concentration-dependent permeability of P-gp substrates. Pharm Res 27:442-446
63. Tachikawa M, Watanabe M, Hori S, Fukaya M, Ohtsuki S, Asashima T, Terasaki T (2005) Distinct spatio-temporal expression of ABCA and ABCG transporters in the developing and adult mouse brain. J Neurochem 95:294-304
64. Takano A, Kusuhara H, Suhara T, Ieiri I, Morimoto T, Lee YJ, Maeda J, Ikoma Y, Ito H, Suzuki K, Sugiyama Y (2006) Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. J Nucl Med 47:1427-1433
65. Takashima T, Yokoyama C, Mizuma H, Yamanaka H, Wada Y, Onoe K, Nagata H, Tazawa S, Doi H, Takahashi K, Morita M, Kanai M, Shibasaki M, Kusuhara H, Sugiyama Y, Onoe H, Watanabe Y (2011) Developmental changes in P-glycoprotein function in the blood-brain barrier of nonhuman primates: PET study with R-11C-verapamil and 11C-oseltamivir. J Nucl Med 52:950-957
66. Tetsuka K, Takanaga H, Ohtsuki S, Hosoya K, Terasaki T (2003) The l-isomer-selective transport of aspartic acid is mediated by ASCT2 at the blood-brain barrier. J Neurochem 87:891-901
67. Tohyama K, Kusuhara H, Sugiyama Y (2004) Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier. Endocrinology 145:4384-4391
68. Toovey S, Rayner C, Prinssen E, Chu T, Donner B, Thakrar B, Dutkowski R, Hoffmann G, Breidenbach A, Lindemann L, Carey E, Boak L, Gieschke R, Sacks S, Solsky J, Small I, Reddy D (2008) Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 31:1097-1114
69. Trajkovic M, Visser TJ, Mittag J, Horn S, Lukas J, Darras VM, Raivich G, Bauer K, Heuer H (2007) Abnormal thyroid hormone metabolism in mice lacking the monocarboxylate transporter 8. J Clin Invest 117:627-635
70. Tsuruoka S, Ishibashi K, Yamamoto H, Wakaumi M, Suzuki M, Schwartz GJ, Imai M, Fujimura A (2002) Functional analysis of ABCA8, a new drug transporter. Biochem Biophys Res Commun 298:41-45
71. Uchida Y, Kamiie J, Ohtsuki S, Terasaki T (2007) Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res 24:2281-2296
72. Uchida Y, Ohtsuki S, Kamiie J, Terasaki T (2011a) Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J Pharmacol Exp Ther 339:579-588
73. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, Terasaki T (2011b) Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 117:333-345
74. Urquhart BL, Kim RB (2009) Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol 65:1063-1070
75. Wang MZ, Wu JQ, Dennison JB, Bridges AS, Hall SD, Kornbluth S, Tidwell RR, Smith PC, Voyksner RD, Paine MF, Hall JE (2008) A gel-free MS-based quantitative proteomic approach accurately measures cytochrome P450 protein concentrations in human liver microsomes. Proteomics 8:4186-4196
76. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492-507
77. Yagi T, Ohkubo M (2010) Cost and time period for drug discovery and development. JPMA Newslett 136:33-35
78. Yoshikawa A, Nakada M, Ohtsuki S, Hayashi Y, Obuchi W, Sato Y, Ikeda C, Watanabe T, Kawahara Y, Hasegawa T, Sabit H, Kita D, Nakanuma Y, Terasaki T, Hamada JI (2012) Recurrent anaplastic meningioma treated by sunitinib based on results from quantitative proteomics. Neuropathol Appl Neurobiol 38:105-110
79. Zhang C, Kwan P, Zuo Z, Baum L (2012) The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev 64:930-942
80. Zorumski CF, Olney JW (1993) Excitotoxic neuronal damage and neuropsychiatric disorders. Pharmacol Ther 59:145-162